Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Background Targeted radionuclide therapy with Actinium-225-labeled prostate-specific
membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality …

Purpose Lutetium-177 prostate-specific membrane antigen-617 (177 Lu-PSMA-617) in end-
stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable …

PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand
therapy (RLT), either as monotherapy or in combination with 177Lu, is a promising therapy …

The aim of the review was to evaluate patient and treatment characteristics for patients with
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …

Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …

[177Lu] Lu-PSMA has recently been approved for use in the post-taxane, post-novel
hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a …

There is now an increasing trend for targeting cancers to go beyond early diagnosis and
actually improve Progression-Free Survival and Overall Survival. Identifying patients who …

Radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA)
inhibitors ([177Lu] Lu-PSMA) is currently approved for patients with metastatic castration …